The Journal of Urology
Volume 180, Issue 4 , Pages 1235-1240, October 2008

Inflammatory Myofibroblastic Tumors of the Genitourinary Tract—Single Entity or Continuum?

  • Liang Cheng

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
    • Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana
    • Corresponding Author InformationCorrespondence and requests for reprints: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th St., Clarian Pathology Laboratory Room 4010, Indianapolis, Indiana 46202 (telephone: 317-491-6442; FAX: 317-491-6419)
  • ,
  • Stephanie R. Foster

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
  • ,
  • Gregory T. MacLennan

      Affiliations

    • Department of Pathology, Case Western Reserve University, Cleveland, Ohio
  • ,
  • Antonio Lopez-Beltran

      Affiliations

    • Department of Pathology, Cordoba University, Cordoba, Spain
  • ,
  • Shaobo Zhang

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
  • ,
  • Rodolfo Montironi

      Affiliations

    • Institute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy

Received 5 April 2008 published online 15 August 2008.

Purpose

Inflammatory myofibroblastic tumor of the genitourinary tract is a spindled soft tissue lesion that is often mistaken for sarcoma. These tumors have been described in numerous sites in the body and have been assigned many names. The relationship between inflammatory myofibroblastic tumor and other morphologically similar entities has been a long-standing source of controversy. We investigated whether inflammatory myofibroblastic tumors in adults and children are the same entity, and whether inflammatory myofibroblastic tumor is part of a biological spectrum that includes benign and malignant entities at opposite ends.

Materials and Methods

We performed an extensive review of the literature.

Results

The literature suggests that with evidence of anaplastic lymphoma kinase rearrangement and expression, the lesion is neoplastic rather than reactive, differentiating it from previously described lesions.

Conclusions

Inflammatory myofibroblastic tumor of the genitourinary tract should be considered a neoplasm of uncertain malignant potential, and routine surveillance and close clinical followup are recommended. Aggressive therapy (radical cystectomy, radiation or chemotherapy) is unwarranted given the indolent and often benign clinical course for the majority of cases. To understand the diagnostic and prognostic implications future emphasis should be placed on the link between genetic abnormalities, and clinical course, therapeutic response and ultimate outcome.

Key Words: urinary bladder, sarcoma, soft tissue neoplasms, immunohistochemistry, carcinosarcoma

Abbreviations and Acronyms: ALK, anaplastic lymphoma kinase, EBV, Epstein Barr virus, FISH, fluorescence in situ hybridization, IMT, inflammatory myofibroblastic tumor, PMP, pseudosarcomatous myofibroblastic proliferation, PSCN, postoperative spindle cell nodule

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Nothing to disclose.

 Editor's Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 1578 and 1579.

PII: S0022-5347(08)01581-4

doi:10.1016/j.juro.2008.06.049

The Journal of Urology
Volume 180, Issue 4 , Pages 1235-1240, October 2008